A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

Also called NCT02119819

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 420 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02119819
  • EudraCT 2013-003552-21
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Greece, Mexico, Poland, Puerto Rico, Romania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02119819. Randomized; double masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2021-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2944876
Intervention (Drug)
Exenatide extended-release
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Lead sponsor
OPKO Health, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02119819
Content hash
da161ea13d4452c0e87c3ad193c1f6e4c0fd25d4db053cba380b778b22fc2a3d